David Bejker, Affibody CEO

Chiesi puts down $200M+ to col­lab­o­rate with Af­fi­body for res­pi­ra­to­ry dis­eases

The Ital­ian drug de­vel­op­er Chiesi will be look­ing to drop nine fig­ures to de­vel­op sev­er­al treat­ments for res­pi­ra­to­ry dis­eases in a deal with Swedish biotech Af­fi­body.

Chiesi and Af­fi­body will work to­geth­er on three pro­grams us­ing Af­fi­body’s mol­e­cules against three tar­gets. Chiesi will al­so fund the dis­cov­ery and de­vel­op­ment work as well as com­mer­cial­ize the can­di­dates world­wide, but Af­fi­body will hold on to co-pro­mot­ing the can­di­dates in the Nordic re­gion.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

Venture & Research Associate

Alexandria Real Estate Equities

San Francisco, CA, USA